TrDizin

Permanent URI for this collectionhttps://hdl.handle.net/11452/21452

Browse

Browsing by BUU Author "Akalın, Halis"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Mediterranean spotted fever: Retrospective evaluation of 16 cases
    (Aves Yayıncılık, 2010-06) Engin, Aynur; Yılmaz, Emel; Akalın, Halis; Mıstık, Reşit; Heper, Yasemin; Kılıçaslan, Ebru; Öztüfekçi, Aslıhan; Sevgican, Emine; Helvacı, Safiye; Töre, Okan; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0002-3894-1231; AAH-6506-2021; AAU-8952-2020; 22037135100; 57207553671; 6602564624; 56191003300; 36179901600; 36180184500; 16246450600; 6602103491; 6505909596
    Objectives: Mediterranean spotted fever (MSF) is an acute febrile, zoonotic disease caused by Rickettsia conorii and endemic infectious disease in Mediterranean countries. Patients and Methods: In this study, a retrospective examination of 16 cases (4 females, 12 males; mean age 38.9 +/- 13.0; range 18 to 64 years) that were diagnosed with rickettsioses between 1987-2007 was performed. Diagnosis of MSF was based upon epidemiological and clinical features, indirect immunofluorescence antibody (IFA), as well as response to doxycycline therapy. Results: High fever and maculopapular rash were present in all cases. Palmar and plantar rash were evident in 13 (81.3%) and eschar in eight (50%) cases. All cases responded to treatment within 2 +/- 0.9 days, and no death was observed. Conclusion: Mediterranean spotted fever should be considered in the differential diagnosis of all patients admitting with fever, maculopapular rash, headache and/or muscle-joint pain during spring, summer and autumn.
  • Thumbnail Image
    Publication
    The outcome of antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: A single-center study
    (Galenos Yayıncılık, 2018-07-26) Özkocaman, Vildan; Özkalemkaş, Fahir; Seyhan, Serdar; Ener, Beyza; Ursavaş, Ahmet; Ersal, Tuba; Kazak, Esra; Demirdöğen, Ezgi; Mıstık, Reşit; Akalın, Halis; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Mikrobiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları ve Tüberküloz Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı.; 0000-0002-4803-8206; 0000-0002-7400-9089; AAI-3169-2021; AAG-8459-2021; AAH-1854-2021; AAJ-4354-2021; AAU-8952-2020; AAG-8523-2021; AAH-9812-2021; AAG-8495-2021; 6603145040; 6601912387; 56154853700; 15053025300; 8329319900; 56061031700; 24921238200; 14062849300; 6602564624; 57207553671
    Objective: Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation. The aim of this study was to evaluate the real-life impact of posaconazole prophylaxis. Materials and Methods: Eighty-four adult patients were included with AML under remission induction chemotherapy and posaconazole prophylaxis. The 34 patients in the control group did not receive primary antifungal prophylaxis. The period between June 2006 and January 2009, when antifungal prophylaxis was not administered (control group), was retrospectively compared to the period between December 2010 and May 2012 when primary oral posaconazole prophylaxis was administered in similar conditions (posaconazole group) according to the use of antifungal agents for treatment, breakthrough infections, galactomannan performance, and the necessity for performing bronchoalveolar lavage (BAL) procedures. Results: The two groups were compared according to the use of antifungal agents; progression to a different antifungal agent was found in 34/34 patients (100%) in the control group and in 9/84 patients (11%) in the posaconazole group (p<0.001). There were four breakthrough IFIs (4/84, 4.8%) in the posaconazole group and 34 IFIs in the control group (p<0.001). In addition, 15/34 patients (44%) in the control group required BAL compared to 11/84 patients (13%) in the posaconazole group (p<0.001). Posaconazole treatment was discontinued within 7-14 days in 7/84 patients (8.3%) due to poor oral compliance related to mucositis after chemotherapy. Conclusion: Posaconazole appears to be effective and well-tolerated protection against IFIs for AML patients.